Transcript of the Earnings Conference call held on 13th August, 2026 for Q1 FY27.

Date: 17th August, 2026 BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street - Fort, Mumbai — 400 001. Ref.: BSE Scrip Code - 539730 Subject: Transcript of the Earnings Conference call held on 13th August 2026 for Q1 FY27. Dear Sir / Madam, In addition to our earlier intimation dated 08th August, 2026 regarding audio recording of the Investors ‘Conference Call and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the transcript of Investors’ Conference Call held on Thursday, 13th August, 2026, at 11:30 a.m. for Q1 & FY27 results. The transcript is also available on Company’s website at: http://www.fredungroup.com/investor-investor- LINK meet.html#investor You are requested to kindly take note of the same. Thanking you, FOR FREDUN PHARMACEUTICALS LIMITED FREDUN MEDHORA MANAGING DIRECTOR DIN: 01745348 “Fredun Pharmaceuticals Limited Q1 FY27 Business Conference Call August 13, 2026 MANAGEMENT: MR. FREDUN MEDHORA – MANAGING DIRECTOR – FREDUN PHARMACEUTICALS LIMITED MODERATOR: MS. SAKHI PANJIYARA – KIRIN ADVISORS Fredun Pharmaceuticals Limited August 13, 2026 Moderator: Ladies and gentlemen, good day, and welcome to the Q1 FY27 Results Conference Call of Fredun Pharmaceuticals Limited. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Sakhi Panjiyara. Thank you, and over to you, ma'am. Sakhi Panjiyara: Good morning, everyone, and thank you for joining the Q1 FY27 Earnings Conference Call of Fredun Pharmaceuticals Limited. We have with us today Mr. Fredun Medhora, Managing Director of the company. Before handing over to Fredun Sir, let me briefly walk you through the company's performance for the first quarter of FY27. During Q1 FY27, stand-alone total income stood at INR228.25 crores, registering a strong Y-on-Y growth of 90.44%. EBITDA stood at INR32.78 crores, reflecting a growth of 92.90% year-on-year growth. EBITDA margin improved to 14.36%, expanded by 18 bps year-on-year. Net profit of the quarter stood at INR13.17 crores, registering a growth of 94.63% year-on-year growth. Net profit margin improved to 5.77%, expanded by 12 basis points. Overall, the company delivered revenue growth during the quarter, along with an improvement in operating margins and profitability. With that brief overview, I would now like to hand over to Mr. Fredun Medhora. We can open the floor for the Q&A. Moderator: The first question is from the line of Vinod Shah from VS Ventures. Vinod Shah: Congrats on a good set of numbers. So you have almost delivered FY23 like full year revenue in this quarter only. So where can we see Fredun in next 3 to 5 years? Fredun Medhora: As I've been always saying, we are -- there are 2 parts of the growth story. One is our new age brands, which are growing at around 35% to 45% year-on-year. Some are growing even faster because they are at a lower base. And our vintage business is growing at around 15% to 20% year-on-year. So a blended growth of somewhere around 35% to 30% for the next 3 years is kind of on the charts and it's going to be a combination of all the new brands and our existing ones, plus the increase in the capacities that we are building currently at our own facility. Page 2 of 12 Fredun Pharmaceuticals Limited August 13, 2026 And also around with our 5 plants in Palghar, we have added around 43 locations where we are manufacturing. So those products will also add in. It will give a very good boost to the sales and the product line in the coming 3 to 5 years. Moderator: The next question is from the line of Mayur Parikh from VY Capital. Mayur Parikh: So I just wanted to know like can you just throw some light on the company's domestic growth opportunity? Like Fredun GX is currently present across 17 states. And our strategy mentions the deeper penetration into Tier 2 and 4 cities. So how large could this opportunity become over the next 2 to 3 years? Fredun Medhora: So GX is currently now in around 19 states. And we are at a very small base of this year, about INR100 crores, INR110 crores only. So we have a very long way to go in terms of GX also, we've got a very good acceptance of our goods. Our goods are very well accepted in the market, plus along with our promoted brands such as our pet care brand, our nutrition brand, our mobility brand, our other products, which are also sold in some -- in common chemist shops. So the pharmacies, the people, the distribution line feel very confident that there is a vast array of products across therapeutic ranges coming from this company, and they are more than willing to hold more and more of our goods and actually sell them. So plus the repeatability of those products are quite high. So we are -- again, the same thing, we are very underpromised kind of people. We expect 25% to 35% growth in this business year-on-year, even for the next 5 years, we don't anticipate any hiccup because we are at a very small base. So we have a long foresight ahead. We have planned for the next 3.5 to 4 years. Anything more than that, I would not want to comment. But for the next 4 years, we can easily consider around 30% to 35% growth on the GX line as well. The market potential is huge. Some big companies are doing thousands of crores of GX. Product penetration -- I mean, I'm talking about pharma penetration itself is very poor in our country even in 2026. There are a lot of people under poverty line as well. So many people are not even having access to medicine for that Fredun GX or anything. So in the next 10 years, definitely, as India progresses, as people come out of the poverty line, even 1% of the people is like a small country in Europe. So we have a long way to go. Our aim is to ensure that our supply chain is robust. Our aim is to ensure that our products reach the customers in time and the product basket keeps on enhancing itself with the latest molecules and with the addition of further products to enhance the product basket as an overall offering. Moderator: The next question is from the line of Keshav Toshniwal from Karnakala Capital. Keshav Toshniwal: Congratulations, Fredun, for excellent set of numbers. Your new website, Wagr.in, looks super interesting. Like if you could expand upon what kind of developments have happened and what you're seeing this pan out like? It's looking excellent website. Page 3 of 12 Fredun Pharmaceuticals Limited August 13, 2026 Fredun Medhora: Thank you. So as we have taken over the website and the company last year, first, we spent about 3 to 4 months creating the team because, as you know, a strong team who has built websites and e- commerce platforms for a long period of time and with successful e-commerce platforms to get that kind of team engaged and formed, it takes time. But luckily, we were lucky enough to find the right kind of people. Then we started onboarding all our brands. Almost all the brands are complete. I think within the next 20 to 25 days, practically every single big brand in the country will be onboarded. We also have now onboarded our pharmacies. So we have a huge, almost 1,500, 2,000 product range of medical products also that you can order from various brands across companies. So it is already one of the most comprehensive pet care portals right now even in our beta phase. We've had a soft launch [Showing first 8,000 characters — download PDF for full document]